Zobrazeno 1 - 10
of 27
pro vyhledávání: ''
Autor:
Suresh G. Nair Md, Jorge A. Rojas Zamalloa, Walid K. Chatila, Jedd D. Wolchok, Daniel G. Coit, Neal Rosen, Francisco Sanchez-Vega, Penina Krieger, Nikolaus Schultz, Klaus J. Busam, Margaret K. Callahan, Parisa Momtaz, Allison Betof Warner, Arshi Arora, Alexander N. Shoushtari, David B. Solit, Charlotte E. Ariyan, Havish S. Kantheti, Katherine S. Panageas, Christopher A. Barker, Mary S. Brady, Paul B. Chapman, Michael A. Postow
Publikováno v:
Clin Cancer Res
Purpose: Cutaneous and unknown primary melanomas frequently harbor alterations that activate the MAPK pathway. Whether MAPK driver detection beyond BRAF V600 is clinically relevant in the checkpoint inhibitor era is unknown. Experimental Design: Pati
Autor:
Brian A. Van Tine, Jennifer A. Wargo, Richard F. Riedel, Emily Z. Keung, Sujana Movva, Jaime Rodrigues-Canales, Hussein Abdul-Hassan Tawbi, Edwin R. Parra, Christina L. Roland, Alexandre Reuben, Melissa Amber Burgess, Lara E. Davis, Denise K. Reinke, Alexander J. Lazar, James C. Hu, Steven Attia, Scott M. Schuetze, Dennis A. Priebat, Ruth Salazar, Vanessa Bolejack, Damon R. Reed, Wei Lien Wang, Scott H. Okuno
Publikováno v:
Clin Cancer Res
Purpose: We recently reported a 17.5% objective RECIST 1.1 response rate in a phase II study of pembrolizumab in patients with advanced sarcoma (SARC028). The majority of responses occurred in undifferentiated pleomorphic sarcoma (UPS) and dedifferen
Autor:
Yi Bai, Ke Hu, Jie Pan, Li Huo, Haitao Zhao, Junping Shi, Lei Zhang, Yan Jiang, Junyu Long, Honglin Guo, Xinting Sang, Xu Yang, Xiaobo Yang, Xueshuai Wan, Kai Wang, Dongxu Wang, Mei Guan, Jianzhen Lin
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(15)
Purpose: Alterations in DNA damage repair (DDR) genes produce therapeutic biomarkers. However, the characteristics and significance of DDR alterations remain undefined in primary liver cancer (PLC). Experimental Design: Patients diagnosed with PLC we
Autor:
Winston W. Huh, Eric M. Rohren, Kalevi Kairemo, Najat C. Daw, Homer A. Macapinlac, Joseph A. Ludwig, David S. Hong, Vivek Subbiah, Peter M. Anderson, Sant P. Chawla, Eugenie S. Kleinerman, Robert S. Benjamin, Vinod Ravi, Funda Meric-Bernstam, Gregory Ravizzini, Kenneth R. Hess, Neeta Somaiah
Publikováno v:
Clin Cancer Res
Purpose: The prognosis of metastatic osteosarcoma continues to be poor. We hypothesized that alpha-emitting, bone-targeting radium 223 dichloride (223RaCl2) can be safely administered to patients with osteosarcoma and that early signals of response o
Autor:
Luciano Castiello, David F. Stroncek, Lauren V. Wood, Jiaqiang Ren, Marianna Sabatino, Hanh Khuu, Jay A. Berzofsky, Masaki Terabe
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(13)
Purpose: Despite the vast number of clinical trials conducted so far, dendritic cell (DC)-based cancer vaccines have mostly shown unsatisfactory results. Factors and manufacturing procedures essential for these therapeutics to induce effective antitu
Autor:
Nitin Mehrotra, Ping Zhao, Tiffany K. Ricks, Candace Gomez-Broughton, Carolyn L. Yancey, Donna Przepiorka, Chia-Wen Ko, Pengfei Song, Robert C. Kane, Richard Pazdur, Deborah Schmiel, Albert Deisseroth, Qing Zhou, Brenda J. Gehrke, Ann T. Farrell, Susan L. Kirshner, Reyes Candau-Chacon, Haw-Jyh Chiu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(18)
On December 3, 2014, the FDA granted accelerated approval of blinatumomab (Blincyto; Amgen, Inc.) for treatment of Philadelphia chromosome–negative relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R/R ALL). Blinatumomab is a re
Autor:
Christopher J. Howe, Deborah L. McCartney, Justin J. Cross, J. Chris Kingswood, Anne E. Tattersfield, Simon R. Johnson, Kate Pointon, Julian R. Sampson, J. Cox, Tim Doyle, Petrus J. de Vries, Peter Watson, Andreas L. Serra, D. Mark Davies
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose: Renal angiomyolipomas are a frequent manifestation of tuberous sclerosis and sporadic lymphangioleiomyomatosis (LAM). These disorders are associated with mutations of TSC1 or TSC2 that lead to overactivation of mTOR complex 1 (mTORC1), sugge
Autor:
Paolo Corradini, Laura Giordano, Alessandro M. Gianni, Massimo Di Nicola, Lucia Farina, Simonetta Viviani, Alfonso Marchianò, Roberto Sorasio, Anna Guidetti, Walter Malorni, Carmelo Carlo-Stella, Domenico Russo, Andrea Anichini, Roberta Mortarini, Silvia L. Locatelli, Anna Dodero
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 20(22)
Purpose: To evaluate safety and activity of perifosine and sorafenib combination therapy in patients with lymphoproliferative diseases. Experimental Design: Patients with relapsed and refractory lymphoproliferative diseases received perifosine (50 mg
Autor:
Zhihong Chi, Bixia Tang, Lili Mao, Siming Li, Xinan Sheng, Lu Si, Bin Lian, Yan Kong, Chuanliang Cui, Jun Guo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 19(16)
Purpose: Mucosal melanoma is rare and associated with extremely poor prognosis. However, standard adjuvant therapy for mucosal melanoma has not been established. We conducted a randomized phase II clinical trial in patients with resected mucosal mela
Autor:
Danping Shen, Xiaolin Zhang, Paul R. Gavine, Kunji Liu, Xiuhua Zhang, Minhua Zhou, Yanping Xu, Lin Zhang, Jingchuan Zhang, Elaine Kilgour, Liang Xie, Xinying Su, Jiafu Ji, Xiaolu Yin, Zeren Gao, Lili Tang, Lianhai Zhang, Beirong Gao, Qunsheng Ji
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 19(9)
Purpose: FGFR gene aberrations are associated with tumor growth and survival. We explored the role of FGFR2 amplification in gastric cancer and the therapeutic potential of AZD4547, a potent and selective ATP-competitive receptor tyrosine kinase inhi